Home / Health / Typhoid's ₹123B Toll: India Battles Superbugs
Typhoid's ₹123B Toll: India Battles Superbugs
25 Mar
Summary
- Antibiotic-resistant typhoid cost India ₹123 billion in 2023.
- Children under 10 bore over half of the economic burden.
- Five states account for 51% of the national costs.
In 2023, typhoid fever exacted a substantial economic toll on India, estimated at ₹123 billion. The majority of this burden, a significant 87%, was attributed to antibiotic-resistant infections. This widespread resistance, particularly to fluoroquinolones, has dramatically escalated costs.
Children under the age of 10 bore the brunt of this economic impact, accounting for more than half of the total expenditure. Households faced the highest financial strain, covering 91% of all expenses. Alarmingly, 70,000 families experienced "catastrophic" health expenditures due to the disease.
Five Indian states—Maharashtra, Uttar Pradesh, Andhra Pradesh (including Telangana), Tamil Nadu, and West Bengal—were estimated to be responsible for 51% of the nationwide costs associated with typhoid. These findings highlight the urgent need for enhanced antibiotic resistance control and inform national health financing policies.
Researchers emphasize that the study provides crucial evidence supporting the introduction of the typhoid conjugate vaccine into India's national immunization schedule. The comprehensive analysis underscores the devastating economic consequences of typhoid, especially fluoroquinolone-resistant strains, on young children and vulnerable households across the country.
